One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Provision of mental health care for patients with cancer
doi : 10.1016/S1470-2045(21)00480-0
Volume 22, Issue 9, September 2021, Page 1199
Genomic-adjusted radiation dose to personalise radiotherapy
OritKaidar-PersonabcPhilipPoortmansdRobertoSalgadoef
doi : 10.1016/S1470-2045(21)00411-3
Volume 22, Issue 9, September 2021, Pages 1200-1201
An important step towards smarter screening for prostate cancer
Caroline MMoorea
doi : 10.1016/S1470-2045(21)00449-6
Volume 22, Issue 9, September 2021, Pages 1201-1202
Talazoparib: a new biomarker-directed therapy in advanced prostate cancer
VincenzaConteducaaUgoDe Giorgia
doi : 10.1016/S1470-2045(21)00450-2
Volume 22, Issue 9, September 2021, Pages 1203-1204
Paving a pathway for drug development in HER2-positive biliary tract cancer
Christopher TChenaLipikaGoyalb
doi : 10.1016/S1470-2045(21)00465-4
Volume 22, Issue 9, September 2021, Pages 1204-1206
Antiangiogenic agents combined with systemic chemotherapy in refractory osteosarcoma
PiotrRutkowskia
doi : 10.1016/S1470-2045(21)00422-8
Volume 22, Issue 9, September 2021, Pages 1206-1207
eGFR and chemotherapy: will removing race create disparities?
Andrew SLeveyaNeil RPoweb
doi : 10.1016/S1470-2045(21)00391-0
Volume 22, Issue 9, September 2021, Pages 1208-1209
Global cancer control: choosing the road less travelled
MiriamMutebi
doi : 10.1016/S1470-2045(21)00461-7
Volume 22, Issue 9, September 2021, Pages 1209-1211
Acute tolerance of Moderna mRNA-1273 vaccine against COVID-19 in patients with cancer treated with radiotherapy
SilviaScocciantiaCamillaDelli PaoliaBarbaraGrilli LeonulliaLisaPaolettiaPaoloAlpiaSaverioCainidRaffaellaBarcaaSimonaFondelliaSerenellaRussoeMarcoPernabMaria SimonaPinobFrancescaMartellafFedericaFurlangAndreaBassetticLuisaFiorettob
doi : 10.1016/S1470-2045(21)00427-7
Volume 22, Issue 9, September 2021, Pages 1212-1214
Clarifying allegations regarding CoEHAR conflicts of interest
GiovanniLi VoltiaRiccardoPolosab
doi : 10.1016/S1470-2045(21)00477-0
Volume 22, Issue 9, September 2021, Page e378
Pembrolizumab monotherapy for high-risk, non-muscle-invasive bladder cancer
Cyrill ARentschaStefanieHayozbRichardCathomasc
doi : 10.1016/S1470-2045(21)00390-9
Volume 22, Issue 9, September 2021, Page e379
Pembrolizumab monotherapy for high-risk, non-muscle invasive bladder cancer – Authors' reply
Arjun VBalaraAshish MKamatbRonaldde WitcKEYNOTE-057 investigators
doi : 10.1016/S1470-2045(21)00478-2
Volume 22, Issue 9, September 2021, Page e380
Asian minorities in Asian countries: intersecting disparities affecting minoritised groups
Edward ChristopherDeeaJoseph APaguiobcJ SethYaobcJasmineLimdGideonLascoef
doi : 10.1016/S1470-2045(21)00350-8
Volume 22, Issue 9, September 2021, Page e381
Non-AIDS-defining cancers in people living with HIV
BaptisteAbbaraJean-PhilippeSpanoaMarianneVeyriaAuroreVozyaJacquesCadranelb
doi : 10.1016/S1470-2045(21)00384-3
Volume 22, Issue 9, September 2021, Page e382
Towards evidence-based personalised precision medicine for Lynch syndrome
PålMøllerabJulian RSampsoncMevDominguez-ValentinbToni TSeppäläde
doi : 10.1016/S1470-2045(21)00400-9
Volume 22, Issue 9, September 2021, Page e383
Stereotactic body radiotherapy for painful spinal metastases
FrancescoCelliniabStefaniaManfridabMaria AntoniettaGambacortaabVincenzoValentiniab
doi : 10.1016/S1470-2045(21)00421-6
Volume 22, Issue 9, September 2021, Page e384
Stereotactic body radiotherapy for painful spinal metastases – Authors' reply
ArjunSahgalaMichaelBrundagebKeyueDingbWendy RParulekarb
doi : 10.1016/S1470-2045(21)00459-9
Volume 22, Issue 9, September 2021, Page e385
Sintilimab plus IBI305 for hepatocellular carcinoma
DavidBomzeaTomerMeirsonbDanielAzoulayc
doi : 10.1016/S1470-2045(21)00388-0
Volume 22, Issue 9, September 2021, Page e386
Sintilimab plus IBI305 for hepatocellular carcinoma
LuoChengaHengXiaoa
doi : 10.1016/S1470-2045(21)00424-1
Volume 22, Issue 9, September 2021, Page e387
Sintilimab plus IBI305 for hepatocellular carcinoma – Author's reply
JiaFan
doi : 10.1016/S1470-2045(21)00479-4
Volume 22, Issue 9, September 2021, Page e388
Correction to Lancet Oncol 2018; 19: 337–46
doi : 10.1016/S1470-2045(21)00475-7
Volume 22, Issue 9, September 2021, Page e389
Correction to Lancet Oncol 2021; 22: 1322–32
doi : 10.1016/S1470-2045(21)00476-9
Volume 22, Issue 9, September 2021, Page e389
Increase in health-care cyberattacks affecting patients with cancer
ElizabethGourd
doi : 10.1016/S1470-2045(21)00451-4
Volume 22, Issue 9, September 2021, Page 1215
Shortage of cancer drugs in Mexico
ManjulikaDas
doi : 10.1016/S1470-2045(21)00452-6
Volume 22, Issue 9, September 2021, Page 1216
WHO releases latest report on the global tobacco epidemic
Talha KhanBurki
doi : 10.1016/S1470-2045(21)00464-2
Volume 22, Issue 9, September 2021, Page 1217
Partnership to tackle HCV in low-income and middle-income countries
ManjulikaDas
doi : 10.1016/S1470-2045(21)00474-5
Volume 22, Issue 9, September 2021, Page 1218
Cancer care in Afghanistan after the Taliban takes over
ManjulikaDas
doi : 10.1016/S1470-2045(21)00481-2
Volume 22, Issue 9, September 2021, Page e390
A decade of strengthening breast oncology in Ethiopia
LesleyTayloraCarolHarrisbTamratAbebecAdamuAddissiedMathewosAssefaeEva JohannaKantelhardtf
doi : 10.1016/S1470-2045(21)00254-0
Volume 22, Issue 9, September 2021, Pages 1219-1220
Pan-cancer prediction of radiotherapy benefit using genomic-adjusted radiation dose (GARD): a cohort-based pooled analysis
Jacob GScottDPhilac†GeoffreySedorMDd†PatrickEllsworthBAdJessica AScarboroughMSacKamran AAhmedMDegDaniel EOliverMDegSteven AEschrichPhDfgMichael WKattanPhDb†Javier FTorres-RocaMDeg†
doi : 10.1016/S1470-2045(21)00347-8
Volume 22, Issue 9, September 2021, Pages 1221-1229
Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trials
JalehFallahMDa†LijunZhangPhDa†AnupAmatyaPhDaYutaoGongPhDaBellindaKing-KallimanisPhDaVishalBhatnagarMDaChanaWeinstockMDaDaniel LSuzmanMDaSundeepAgrawalMDaElaineChangMDaMitchell SAnscherMDaDow-ChungChiMDaJames XXuMDaJamie RBrewerMDaMichael HBraveMDaMehrnooshHadadiMDaMarc RTheoretMDabPaul GKluetzMDabKirsten BGoldbergMAabAmnaIbrahimMDaShenghuiTangPhDaRichardPazdurMDabJulia ABeaverMDabLalehAmiri-KordestaniMDaHarpreetSinghMDab
doi : 10.1016/S1470-2045(21)00334-X
Volume 22, Issue 9, September 2021, Pages 1230-1239
Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial
TobiasNordströmMDabAndreaDiscacciatiPhDaMartinBergmanMDagMarkClementsPhDaMarkusAlyMDacdMagnusAnnerstedtMDhAxelGlaessgenMDeStefanCarlssonMDcdFredrikJäderlingMDcfMartinEklundPhDa†ProfHenrikGrönbergMDag†
doi : 10.1016/S1470-2045(21)00348-X
Volume 22, Issue 9, September 2021, Pages 1240-1249
Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial
ProfJohann Sde BonoPhDaNivenMehraPhDbProfGiorgio VScagliottiMDdElenaCastroPhDeTanyaDorffMDfAdamStirlingMDgProfArnulfStenzlMDhMark TFlemingMDiCelestia SHiganoMDjFredSaadMDkConsueloButtiglieroPhDdInge Mvan OortPhDcA DouglasLairdPhDlMarielenaMataPhDlHsiang-ChunChenPhDlCynthia GHealyBSmAkosCzibereMDnProfKarimFizaziMDo
doi : 10.1016/S1470-2045(21)00376-4
Volume 22, Issue 9, September 2021, Pages 1250-1264
Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis
XiaoxiangZhouMDa*ZhuoranYaoMDb*HuaBaiMDbProfJianchunDuanMDbProfZhijieWangMDbXinWangMDaXueZhangMDbJiachenXuMDbKailunFeiMDbZhenZhangMDaFengweiTanMDaProfQiXueMDaProfShugengGaoMDaYiboGaoMDac†ProfJieWangMDbc†ProfJieHeMDac†
doi : 10.1016/S1470-2045(21)00333-8
Volume 22, Issue 9, September 2021, Pages 1265-1274
Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial
ProfBradley JMonkMDabc†NicolettaColomboMDdeProfAmit MOzaMDfProfKeiichiFujiwaraMDgProfMichael JBirrerMDhProfLeslieRandallMDiElena VPoddubskayaMDjkProfGiovanniScambiaMDlYaroslav VShparykMDmMyong CheolLimMDnSnehalkumar MBhoolaMDbopProfJoohyukSohnMDqKanYonemoriMDrRoss AStewartPhDstXiaoxiZhangPhDuJuliaPerkins SmithMDuCarlosLinnMDvProfJonathan ALedermannMDw†
doi : 10.1016/S1470-2045(21)00342-9
Volume 22, Issue 9, September 2021, Pages 1275-1289
Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study
ProfMilindJavleMDaMitesh JBoradMDbNilofer SAzadMDcProfRazelleKurzrockMDdProfGhassan KAbou-AlfaMDefBenGeorgeMDgJohnHainsworthMDhiProfFundaMeric-BernstamMDaProfCharlesSwantonFRCPjkProfChristopher JSweeneyMBBSlClaire FFriedmanMDefRonBoseMDmDavid RSpigelMDhiYongWangMSnJonathanLevyPhDnKatjaSchulzePhDnVaikunthCuchelkarMBBSnArishaPatelMDnHowardBurrisMDhi
doi : 10.1016/S1470-2045(21)00336-3
Volume 22, Issue 9, September 2021, Pages 1290-1300
The impact of scaling up access to treatment and imaging modalities on global disparities in breast cancer survival: a simulation-based analysis
Zachary JWardPhDaProfRifatAtunFRCPbcProfHedvigHricakMDdKwaneleAsanteMScfGeraldineMcGintyMDgElizabeth JSuttonMDdLarryNortonMDeProfAndrew MScottMDhijkProfLawrence NShulmanMDl
doi : 10.1016/S1470-2045(21)00403-4
Volume 22, Issue 9, September 2021, Pages 1301-1311
Lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma (ITCC-050): a multicentre, open-label, multicohort, phase 1/2 study
NathalieGasparMDaRajkumarVenkatramaniMDbStefanieHecker-NoltingMDcProfSoledad GallegoMelconMDdProfFrancoLocatelliMDeFranciscoBautistaMDfAlessandraLonghiMDgCyrilLervatMDhProfNatachaEntz-WerleMDiMichelaCasanovaMDjIsabelleAertsMDkSandra JStraussMDlEstelleThebaudMDmProfBruceMorlandMDnAdela CañeteNietoMDoPerrineMarec-BerardMDpMarionGambartMDqProfClaudiaRossigMDrChinyere EOkparaPhDsCixinHePhDtLeaDuttaPharmDtQuentinCampbell-HewsonMBChBu
doi : 10.1016/S1470-2045(21)00387-9
Volume 22, Issue 9, September 2021, Pages 1312-1321
Pulse therapy with vincristine and dexamethasone for childhood acute lymphoblastic leukaemia (CCCG-ALL-2015): an open-label, multicentre, randomised, phase 3, non-inferiority trial
WenyuYangMDa*JiaoyangCaiMDb*ShuhongShenMDb*JuGaoMDc*JieYuMDd*ShaoyanHuMDe*HuaJiangMDfYongjunFangMDgChangdaLiangMDhProfXiuliJuMDiXuedongWuMDjXiaowenZhaiMDkXinTianMDlNinglingWangMDmProfAiguoLiuMDnHuiJiangMDoProfRunmingJinMDpProfLirongSunMDqMinghuaYangMDrAlex W KLeungMBChBsProfKailiPanMDtYingchiZhangPhDaJingChenMDbYipingZhuMDcHuiZhangMDfChunfuLiMDjJun JYangPhDxChengChengPhDw†ProfChi-KongLiMDs†JingyanTangMDb†XiaofanZhuMDa†ProfChing-HonPuiMDuvy†
doi : 10.1016/S1470-2045(21)00328-4
Volume 22, Issue 9, September 2021, Pages 1322-1332
Effect of removing race from glomerular filtration rate-estimating equations on anticancer drug dosing and eligibility: a retrospective analysis of National Cancer Institute phase 1 clinical trial participants
Morgan ACasalPharmDaS PercyIvyMDcProfJan HBeumerPharmDbdf†Thomas DNolinPharmDae†
doi : 10.1016/S1470-2045(21)00377-6
Volume 22, Issue 9, September 2021, Pages 1333-1340
Radiotherapy resources in Africa: an International Atomic Energy Agency update and analysis of projected needs
Shekinah N CElmoreMDabAlfredoPoloMDcJean-MarcBourqueMDdeYaroslavPyndaPhDcProfDebbievan der MerwePhDcSurbhiGroverMDfKirstenHopkinsMBBScEduardoZubizarretaMDcProfMayAbdel-WahabMDc
doi : 10.1016/S1470-2045(21)00351-X
Volume 22, Issue 9, September 2021, Pages e391-e399
Transforming Canada's role in global cancer control
DanielleRodinMDabAnna JDareMBChBeReanneBookerMNfProfChristopherBoothMDgHeatherBryantPhDhOphiraGinsburgMDciMeredithGiulianiMBBSabProfMaryGospodarowiczMDabSumitGuptaMDdjNazikHammadMDgZeevRosbergerPhDkSimonSutcliffeMDlProfCraig CEarleMDh
doi : 10.1016/S1470-2045(21)00374-0
Volume 22, Issue 9, September 2021, Pages e400-e409
The UK's contribution to cancer control in low-income and middle-income countries
SusannahStanwayMDaMarkLodgeBScabProfRichardSullivanPhDcKimDiproseMScaProfAnnie MYoungPhDadNigelCrispMAePhilippaLewisFRCRfProfTimEdenFRCPghAjayAggarwalPhDiAmandaNadinBScaProfFrankChinegwundohMSjBhawnaSirohiFRCPkProfGedByrneMDlmProfRichardCowanMDahn
doi : 10.1016/S1470-2045(21)00380-6
Volume 22, Issue 9, September 2021, Pages e410-e418
Pneumocephalus as a complication of basal cell carcinoma
BojanMileticPhDaLouiede MeuronMDb
doi : 10.1016/S1470-2045(21)00212-6
Volume 22, Issue 9, September 2021, Page e419
